Halfordinol



Compound IDCDAMM01419
Common nameHalfordinol
IUPAC name4-(2-pyridin-3-yl-1,3-oxazol-5-yl)phenol
Molecular formulaC14H10N2O2

Experimental data

Retention time8.47
Adduct[M+Na]+
Actual mz261.06
Theoretical mz261.063
Error12.33
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.2401

Identifiers and class information

Inchi keyFUXBKWOAAPDDGE-UHFFFAOYSA-N
SmilesOC1=CC=C(C=C1)C=2OC(=NC2)C3=CN=CC=C3
SuperclassOrganoheterocyclic compounds
ClassAzoles

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)1
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)0
Molecular weight (mol_MW)238.245
Computed dipole moment(dipole)4.746
Total solvent accessible surface area (SASA)481.805
Hydrophobic component of SASA (FOSA)0
Hydrophilic component of SASA (FISA)103.712
Pie component of the SASA (PISA)378.093
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)791.457
Number of hydrogen bond donors (donorHB)1
Number of hydrogen bond acceptors (accptHB)4.25
Free energy of solvation of dipole (dip^2/V)0.0284651
Index of cohesive interaction in solids (ACxDN^.5/SA)0.008821
Globularity descriptor (glob)0.85884
Predicted polarizability in cubic angstroms (QPpolrz)28.489
Predicted hexadecane/gas partition coefficient (QPlogPC16)9.092
Predicted octanol/gas partition coefficient (QPlogPoct)13.511
Predicted water/gas partition coefficient (QPlogPw)9.586
Predicted octanol/water partition coefficient (QPlogPo/w)2.205
Predicted aqueous solubility (QPlogS)-3.439
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.412
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.619
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1028.96
Predicted brain/blood partition coefficient (QPlogBB)-0.434
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)510.212
Predicted skin permeability, log Kp (QPlogKp)-2.003
PM3 calculated ionization potential (IP(ev))8.756
PM3 calculated electron affinity (EA(eV))0.966
Number of likely metabolic reactions (#metab)4
Prediction of binding to human serum albumin (QPlogKhsa)-0.066
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)93.774
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)55.117
Number of nitrogen and oxygen atoms (#NandO)4
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P11509CYP2A6Cytochrome P450 2A6T06455SEA
P15538CYP11B1Cytochrome P450 11B1T84621SEA
P19099CYP11B2Cytochrome P450 11B2T59056SEA
O00519FAAHAnandamide amidohydrolaseT11754SEA
P11511CYP19A1Cytochrome P450 19A1T13260SEA
P55072VCPTransitional endoplasmic reticulum ATPaseT12646SEA
P05093CYP17A1Cytochrome P450 17A1T89041SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P49763PGFPlacenta growth factorT70792SEA
O60760HPGDSHematopoietic prostaglandin D synthaseT19433SEA
P42224STAT1Signal transducer and activator of transcription 1-alpha/betaT64205SEA
P40337VHLVon Hippel-Lindau disease tumor suppressor/Elongin B/Elongin CT80423SEA
Q9Y337KLK5Kallikrein 5T11808SEA
P30532CHRNA5Nicotinic acetylcholine receptor alpha4/beta2/alpha5T00299SEA
Q9P0G3KLK14Kallikrein-14T39195SEA
P20813CYP2B6Cytochrome P450 2B6T11793SEA
Q96HK3CALMCalmodulinT39610SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T06455DI0283Mycosis fungoides[ICD-11: 2B01]P11509CYP2A6
T06455DI0351Psoriasis[ICD-11: EA90]P11509CYP2A6
T84621DI0062Breast cancer[ICD-11: 2C60-2C6Y]P15538CYP11B1
T84621DI0108Cushing syndrome[ICD-11: 5A70]P15538CYP11B1
T59056DI0190Hypertension[ICD-11: BA00-BA04]P19099CYP11B2
T11754DI0101Corneal disease[ICD-11: 9A76-9A78]O00519FAAH
T13260DI0062Breast cancer[ICD-11: 2C60-2C6Y]P11511CYP19A1
T13260DI0108Cushing syndrome[ICD-11: 5A70]P11511CYP19A1
T12646DI0012Acute myeloid leukaemia[ICD-11: 2A60]P55072VCP
T12646DI0274Multiple myeloma[ICD-11: 2A83]P55072VCP
T12646DI0284Myelodysplastic syndrome[ICD-11: 2A37]P55072VCP
T12646DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P55072VCP
T89041DI0346Prostate cancer[ICD-11: 2C82]P05093CYP17A1
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T70792DI0095Colorectal cancer[ICD-11: 2B91]P49763PGF
T19433DI0148Flatworm infection[ICD-11: 1F70-1F86]O60760HPGDS
T64205DI0383Skin and skin-structure infection[ICD-11: 1F28-1G0Z]P42224STAT1
T39610DI0068Cardiac arrhythmia[ICD-11: BC9Z]Q96HK3CALM
T39610DI0243Malaria[ICD-11: 1F40-1F45]Q96HK3CALM
T39610DI0370Schizophrenia[ICD-11: 6A20]Q96HK3CALM

Copyright © 2025